

Remedy for the treatment of gout.
ATH: Colchicine
Pharmacodynamics:
The anti-gout effect of colchicine is associated with a decrease in leukocyte migration to the focus of inflammation and inhibition of phagocytosis of uric acid salt microcrystals. It also has an antimitotic effect, inhibits (fully or partially) cell division in the anaphase and metaphase stages, prevents neutrophil degranulation. Reducing the formation of amyloid fibrils, prevents the development of amyloidosis.
Highly effective for relieving acute gout. In the first 12 hours of therapy, the condition significantly improves in more than 75% of patients. 80% can cause adverse reactions from the gastrointestinal tract before clinical improvement or at the same time.
At a daily dose of 1-2 mg when taken daily in 3/4 patients with gout reduces the likelihood of recurrent acute attacks.
Warns acute attacks in patients with familial Mediterranean fever (lowers dopamine-beta-hydroxylase activity).
Increases the life expectancy of patients with primary AL amyloidosis.
It has a positive effect on the skin (softening, reducing dryness) with systemic scleroderma.
Pharmacokinetics:
Colchicine is rapidly and rapidly absorbed from the gastrointestinal tract. The average maximum plasma concentration is 4.2 ng / ml and is reached approximately 70 minutes after administration at a dose of 1 mg. The half-life is 9.3 hours. Colchicine quickly penetrates the tissue, has a high volume of distribution of 473 liters. High concentrations of colchicine are found in the liver, kidneys, spleen, leukocytes and gastrointestinal tract. Colchicine is metabolized in the liver and excreted mainly with bile.
Enterohepatic circulation is detected 4-6 hours after oral administration. The largest part of the injected dose is excreted through the intestines and about 23% through the kidneys.
Acute gout attacks.
Prevention of acute attacks of gout in combination with uricosuric drugs.
Periodic illness (familial Mediterranean fever).
To avoid complications, use only after consulting a doctor.
1 coated tablet contains:
Active ingredient: Colchicum autumn seed extract [eq. 500 mcg of colchicine] [in the composition of the extract 57-64% lactose, 28-32% microcrystalline cellulose] 15.6 mg;
Excipients:
Core
Copovidone 5.33 mg
Corn starch 27.5 mg
Lactose monohydrate 41.6-43.9 mg
Magnesium stearate 0.33 mg
Palmitostearic acid 1.34 mg
Talc 7.00 mg
Microcrystalline cellulose 3.6-5.2 mg
Shell
Acacia gum 0.3 mg
Carnauba wax 0,140 mg
Carmellose sodium 0,273 mg
Magnesium oxide 2.6 mg
Macrogol 6000 1,093 mg
Opalux AS 250000
[sucrose - 0,7923 mg
dye
Ponso 4R (E124) - 0.26334 mg,
quinoline dye
yellow (Е104) - 0.09652 mg,
titanium dioxide (E171) 0.07904 mg,
Povidone 0.0133 mg] 1.2445 mg
Povidone - K 25 2.186 mg
Sucrose 86.1515 mg
Talc 11, 975 mg
Titanium dioxide (E171) 3.717 mg
Shellac 0.32 mg
No customer reviews for the moment.
In the case of an acute gout attack, first take 2 dragees with sugar coating (1 mg of colchicine), and then 1–3 dragees (0.5–1.5 mg of colchicine) every 1–2 hours until the pain subsides. The total dose of the drug taken per day should not exceed 16 pills (8 mg of colchicine). For the prevention of acute attacks of gout in the first few months of treatment with uricosuric drugs take 1-3 pills with sugar coating (0.5-1.5 mg of colchicine) daily or every other day, usually for 3 months.
Sugar coated dragees are swallowed whole, not chewed and squeezed with a sufficient amount of liquid.
Repeated treatment of an acute attack of gout can be carried out no earlier than after 3 days.
Diarrhea, nausea, vomiting and stomach pain may occur. Rare cases of leukopenia (a decrease in the number of white blood cells) have been reported. In some cases, after long-term treatment, myoneuropathy (weakness of muscles and nerve tissues) was observed, less often agranulocytosis, hypoplastic anemia (change in the number of blood corpuscles), skin changes and alopecia (baldness).
Hypersensitivity, pregnancy, lactation, hepatic and / or renal failure, pronounced inhibition of bone marrow hematopoiesis.
Lactose intolerance, lacgas deficiency, sucrase / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption. Children's age up to 18 years.
Carefully:
Patients with diabetes (due to the content of sucrose and lactose in the composition of the drug).
In combination with cyclosporine, especially in patients with impaired kidney function, the likelihood of myopathy increases.
Enhances the effect of depriming and sympathomimetic drugs.
Violates the absorption of cyanocobalamin.
Non-steroidal anti-inflammatory drugs and other drugs that cause myelodepression increase the risk of leukopenia and thrombocytopenia.
Anti-gout activity is reduced by cytostatics (increases the concentration of uric acid) and acidifying preparations of urine, which alkalize, enhance the effect.
Kolhikum-Dispert® can be used in combination with allopurinol and preparations of uricosuric action.
Kolkhikum-Dispert® is contraindicated during pregnancy and lactation.
Treatment should be carried out under careful hematological and clinical control.
With the appearance of pronounced side effects from the gastrointestinal tract, reduce the dose or discontinue the drug.
With a decrease in the number of leukocytes below 3000 / μl and platelets below 100000 / μl, the administration is stopped until the blood picture is normalized.
Impact on the ability to drive trans. Wed and fur .:
Does not affect.
Acute intoxication was observed in adults after taking a dose of about 20 mg and in children after taking a dose of 5 mg.
Chronic intoxication can be observed in patients with gout after taking a total dose of 10 mg or more for several days.
Since colchicine has antimitotic activity, organs that are characterized by a high proliferation rate are more often affected.
Studies and clinical trials of Colchicine (Click to expand)